Burt Wealth Advisors increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 0.8% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 3,040 shares of the medical research company’s stock after acquiring an additional 25 shares during the period. Burt Wealth Advisors’ holdings in Amgen were worth $523,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp raised its position in shares of Amgen by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 8,555,356 shares of the medical research company’s stock valued at $1,403,676,000 after acquiring an additional 195,200 shares in the last quarter. Legal & General Group Plc grew its stake in Amgen by 2.5% during the 2nd quarter. Legal & General Group Plc now owns 3,721,359 shares of the medical research company’s stock worth $640,938,000 after buying an additional 90,615 shares during the last quarter. Schwab Charles Investment Management Inc. grew its stake in Amgen by 2.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 2,962,595 shares of the medical research company’s stock worth $510,248,000 after buying an additional 67,815 shares during the last quarter. UBS Asset Management Americas Inc. grew its stake in Amgen by 3.1% during the 1st quarter. UBS Asset Management Americas Inc. now owns 2,719,874 shares of the medical research company’s stock worth $446,250,000 after buying an additional 81,362 shares during the last quarter. Finally, Swiss National Bank grew its stake in Amgen by 26.5% during the 1st quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock worth $432,490,000 after buying an additional 551,600 shares during the last quarter. 78.54% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.watchlistnews.com/burt-wealth-advisors-buys-25-shares-of-amgen-inc-amgn/1692040.html.

Shares of Amgen Inc. (AMGN) opened at $174.00 on Friday. The firm has a market capitalization of $126,003.56, a price-to-earnings ratio of 13.80, a P/E/G ratio of 2.51 and a beta of 1.37. Amgen Inc. has a twelve month low of $138.83 and a twelve month high of $191.10. The company has a current ratio of 6.07, a quick ratio of 5.72 and a debt-to-equity ratio of 1.05.

Amgen (NASDAQ:AMGN) last released its earnings results on Wednesday, October 25th. The medical research company reported $3.27 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.11 by $0.16. The company had revenue of $5.77 billion during the quarter, compared to analysts’ expectations of $5.75 billion. Amgen had a return on equity of 29.90% and a net margin of 35.54%. The business’s revenue for the quarter was down .7% on a year-over-year basis. During the same period last year, the firm earned $3.02 EPS. equities analysts anticipate that Amgen Inc. will post 12.66 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Investors of record on Friday, November 17th will be paid a dividend of $1.15 per share. The ex-dividend date is Thursday, November 16th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.64%. Amgen’s dividend payout ratio (DPR) is presently 41.63%.

Amgen announced that its Board of Directors has approved a share repurchase plan on Wednesday, October 25th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.

AMGN has been the subject of a number of recent research reports. Mizuho restated a “buy” rating and set a $183.00 price objective (down from $195.00) on shares of Amgen in a research note on Monday, August 21st. BidaskClub downgraded Amgen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Argus increased their price target on Amgen from $180.00 to $195.00 and gave the stock a “buy” rating in a research note on Thursday, July 27th. Cann reissued a “buy” rating and issued a $203.00 price target (up previously from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $195.00 price target on shares of Amgen in a research note on Monday, July 17th. Thirteen equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. Amgen presently has an average rating of “Buy” and a consensus target price of $190.03.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of Amgen stock in a transaction dated Monday, October 9th. The stock was sold at an average price of $185.95, for a total transaction of $283,573.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Carbonnel Francois De sold 4,000 shares of Amgen stock in a transaction dated Wednesday, November 8th. The stock was sold at an average price of $173.61, for a total value of $694,440.00. The disclosure for this sale can be found here. 0.19% of the stock is owned by insiders.

About Amgen

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.